CG Bio Inc.
CG Bio Inc. is a total healthcare provider with a goal of enhancing the quality of life by offering range of innovative solutions for the spectrum of spinal disorders and wound management. Through extensive research activity, CG Bio is a leading manufacturer and distributor of comprehensive portfolio of allograft and synthetic bone grafts, spinal implants, GMP grade growth factors and total wound care solution. CG Bio has state of the art facility with class 100 clean rooms, purified water system fit for human injection and qualified technicians.Cell & Growth Factor Biotechnology
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2006
About Us
Mission
Through advanced regenerative medical technology, we help many people lead a young and healthy life
Vision
Global No. 1 company specialized in regenerative medicine with growth and profitability based on biomaterial technology
Business
Areas Specialized in regenerative medicine based on “Biomaterial Technology
Business Area
- rhBMP-2, Growth Factor
- Allograft
- Interbody Fusion Device
- Pedicle Internal Fixation System
- Bone Hemostasis Agent
- Acellular Dermal Matrix
- Negative Pressure Wound Therapy
- Hydrocolloid & Foam dressing
- rhEGF, rhFGF (growth factors)
- Anti-adhesion barrier
- Dermal Filler
- Breast Augmentation
- Stem Cell Therapy
- Coronary Stent, Catheter
- Neuro Stent, Catheter
- Gastrointestinal Stent
- 3D Printed Implants
- 3D Printer
Global Business
CG Bio Inc. is founded in 2006, under the family of the Daewoong Group with strong coherence to the Company’s core values such as Justice, Open-minded, Fairness, win-win-win and Ownership. We are one of the leading Surgical Devices manufacturer and distributor in South Korea, providing total wound management solutions and a broad spectrum of bone products for Orthopedic & Dental use. At CG Bio, we are dedicated in providing high quality products portfolio of allograft, DBM, synthetic bone grafts, spinal implants, NPWT, Growth factors and advanced wound dressings. Our state of the art facility with 100 clean rooms, purified water system fit for human injection and well qualified technicians.
Nurturing Professional Education & Training
There are a number of changes affecting health care delivery, including a shift from acute to chronic care, the need to integrate a continually expanding evidence base and technological innovations, more clinical practice occurring in teams, complex treatment modalities and changing patient-clinician relationships. Future discoveries in wound care and bone care depend on bolstering the scientific literacy of young doctors today. Our Daewoong Foundation together with our Global marketing initiatives will continue our customer center and encourage medical practices sharing and research participation. By bringing together practitioners, patients, medical societies, public and private stakeholders, we believe that benefits to patients and to society as a whole in addition to those of the research itself is leading to advances in health care.
Enhancing the Workplace
Ultimately, it is our colleagues who make a successful company. Our successes in the future are the result of the enthusiasm and hard work of our very special employees who are motivated to perform in a complex multicultural environment, delivering world-class services and products to our partners and patients. They are proud to be the driving force of this pioneering organization, forging new healthcare models in one of the largest and most dynamic regions of the world. CG Bio remains devoted to our employees’ ongoing development and training, empowering them to work together on our important ongoing initiatives.
History
2016
- New Technology Certification for treatment for Hemorrhagic Gastrointestinal Disease Treatment for Endoscopy using epithelial cell growth factor
- Received IR52 Jang Young-Sil Award for Technological Innovation
- First approval in Korea of NOVOSIS, a medical device with fusion of bone graft-promoting protein ‘rhBMP-2’ and bone graft material
- Selected as an Excellent Technology Research Center from Ministry of Trade, Industry and Energy.
- Acquirement of certification for New Health Technology (NET)
2015
- Achieved ‘Million Dollar Export Tower’ on Trade Day
- Jang Young-Sil Award / Minister of Industry Award / Certified for New Health Technology
2013
- CE Certification
- Acquired FDA approval for CuraVAC (medical device)
2011
- ISO 13485 Granted
2010
- Medical equipment manufacturing license register
- Approval of Good Manufacturing Practice Regulations (GMP)
2009
- Inobiz Accreditation/Certification
2008
- Human Tissue FDA Registration / Registration as a venture company
2007
- Tissue bank authorization/ establishment of Corporate Research Center
2006
- Founding of CGBio